Hiddo J.L. Heerspink

Initial Changes in eGFR during Treatment with Balcinrenone and Dapagliflozin

Introduction: The novel non-steroidal mineralocorticoid receptor antagonist balcinrenone in combination with dapagliflozin reduced urinary albumin-to-creatinine ratio (UACR) over 12 weeks in the MIRO-CKD phase 2 trial in chronic kidney disease (CKD) and induced a modest acute eGF...

Efficacy and safety of canagliflozin are consistent across polypharmacy burden in CKD: the CREDENCE trial

Abstract Background Polypharmacy in chronic kidney disease (CKD) is substantial. Clinicians and patients are often reluctant to add medications to already complex regimens, partly due to concerns about diminishing efficacy and increased adverse effects. We assessed whether effica...

Meta-regression model choice and the interpretation of trial-level surrogacy

The use of surrogate endpoints can improve feasibility of clinical trials. The results of trial-level analyses are a key factor affecting regulatory policy regarding the uptake of a surrogate endpoint. Trial-level analyses aim to quantify the strength of association between treat...